Key result
Iron chelation therapy with dexrazoxane (ICRF-187) has a potent cardioprotective effect against anthracycline-mediated cardiotoxicity and may enhance antitumour activity.
Why the study?
Does dexrazoxane provide cardioprotection against anthracycline-mediated cardiotoxicity?
Does dexrazoxane provide cardioprotection against anthracycline-mediated cardiotoxicity?
Dexrazoxane acts as a potent cardioprotective agent against anthracycline-induced cardiotoxicity through iron chelation.
May support dexrazoxane for anthracycline cardiotoxicity; leaves open optimal iron-targeted strategies and mechanisms.
The cardiotoxic effect of anthracyclines limits their use in the treatment of a variety of cancers. The reason for the high susceptibility of cardiac muscle to anthracyclines remains unclear, but it appears to be due, at least in part, to the interaction of these drugs with intracellular iron (Fe). The suggestion that Fe plays an important role in anthracycline cardiotoxicity has been strengthened by observation that the chelator, dexrazoxane (ICRF-187), has a potent cardioprotective effect. In the present review, the role of Fe in the cardiotoxicity of anthracyclines is discussed together with the possible role of Fe chelation therapy as a cardioprotective strategy that may also result in enhanced antitumour activity.
No takes yet. Share an insight, caveat, or question.
Kwok et al. (2000) conducted a review in Anthracycline-mediated cardiotoxicity. Dexrazoxane (ICRF-187) was evaluated. Iron chelation therapy with dexrazoxane (ICRF-187) has a potent cardioprotective effect against anthracycline-mediated cardiotoxicity and may enhance antitumour activity.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: